HIRA to curb NHI payment on Zyprexa

Published: 2002-10-02 06:58:00

Updated: 2002-10-02 06:58:00

The Health Insurance Review Agency (HIRA) decided to control the NHI payment on Zyprexa, a major tranquilizer (E. Lilly) by classifying it as the 2nd choice of drugs, on the ground that it had no any significant difference in its therapeutic effect with other preparations except a minor side effe...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK